Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Income from Continuing Operations (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Income from Continuing Operations for 14 consecutive years, with 38000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations fell 99.09% year-over-year to 38000.0, compared with a TTM value of 2538000.0 through Dec 2025, up 77.98%, and an annual FY2025 reading of 10195000.0, up 27.23% over the prior year.
  • Income from Continuing Operations was 38000.0 for Q4 2025 at Heron Therapeutics, up from 4093000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 4173000.0 in Q4 2024 and bottomed at 62923000.0 in Q1 2022.
  • Average Income from Continuing Operations over 5 years is 25858350.0, with a median of 22642000.0 recorded in 2022.
  • Peak annual rise in Income from Continuing Operations hit 165.74% in 2025, while the deepest fall reached 99.09% in 2025.
  • Year by year, Income from Continuing Operations stood at 53537000.0 in 2021, then soared by 61.98% to 20355000.0 in 2022, then skyrocketed by 49.79% to 10220000.0 in 2023, then surged by 140.83% to 4173000.0 in 2024, then crashed by 99.09% to 38000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for HRTX at 38000.0 in Q4 2025, 4093000.0 in Q3 2025, and 1637000.0 in Q2 2025.